Receptor Life Sciences Australia

Receptor Life Sciences Australia is a clinical-stage biotechnology company focused on developing high-performance cannabinoid-based therapies for central nervous system (CNS) disorders. The company utilizes validated drug delivery technologies, including the Technosphere inhalation platform licensed from MannKind Corporation, to provide rapid-onset and consistent delivery of cannabinoids. Its lead program, RLS103, is an inhaled dry powder cannabidiol (CBD) being evaluated for the treatment of social anxiety disorder and acute epilepsy. The company's pipeline also includes inhaled and oral formulations for migraine and chronic pain. As of mid-2024, the company has initiated voluntary deregistration of its Australian operations, reflecting a wind-down of its regional activities.